Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | QPCT | Q16769 | 15/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16450872 | 0.83 | QPCT (0.72) | CYP1A2CYP3A4CYP2D6CYP2C9HSD17B10 | |
| SCHEMBL10310206 | 0.83 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2D6CYP2C9HSD17B10 | |
| SCHEMBL4823052 | 0.83 | L3MBTL1 (0.66) | CYP1A2CYP3A4CYP2D6CYP2C9HSD17B10 | |
| SCHEMBL77540 | 0.81 | QPCT (1.00) | CYP1A2CYP3A4CYP2D6CYP2C9HSD17B10 | |
| SCHEMBL16449777 | 0.80 | QPCT (0.70) | CYP1A2CYP3A4CYP2D6CYP2C9HSD17B10 | |
| SCHEMBL10219887 | 0.80 | QPCT (0.89) | CYP1A2CYP3A4CYP2D6CYP2C9HSD17B10 | |
| SCHEMBL13655177 | 0.79 | SMN1; SMN2 (0.72) | CYP1A2CYP3A4CYP2D6CYP2C9HSD17B10 | |
| SCHEMBL18544251 | 0.79 | L3MBTL1 (0.69) | CYP1A2CYP3A4CYP2D6CYP2C9HSD17B10 | |
| SCHEMBL18317579 | 0.78 | L3MBTL1 (0.68) | CYP1A2CYP3A4CYP2D6CYP2C9HSD17B10 | |
| SCHEMBL6398857 | 0.78 | L3MBTL1 (0.68) | CYP1A2CYP3A4CYP2D6CYP2C9HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150561-B2 | Thiazole derivatives and use thereof | MERCK SERONO S.A. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-8889709-B2 | Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions | PROBIODRUG AG (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | MERCK SERONO S.A. (CH) | 2014-08-14 | — | — | US | disclosed |
| US-8802861-B2 | Thiazole derivatives and use thereof | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-8647834-B2 | Screening method for enzyme inhibitors | PROBIODRUG AG (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120183974-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2010-05-20 | — | — | US | disclosed |
| US-20100009337-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-01-14 | — | — | US | disclosed |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20080249083-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-09 | — | — | US | disclosed |
| EP-1709019-B1 | THIAZOLE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228365-A1 | THIAZOLE DERIVATIVES AND USE THEREOF | PF4, TEC, PDGFRB | CYP1A2 2522/4885CYP3A4 1675/4885CYP2D6 2940/4885 |
| US-20090029998-A1 | Thiazole Derivatives and Use Thereof | PDGFRB, PDGFRA, TEC | CYP1A2 2078/4885CYP3A4 1474/4885CYP2D6 3205/4885 |
| US-20080249083-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | QPCT, QPCTL, GLUL | CYP1A2 4269/4885CYP3A4 3923/4885CYP2D6 3541/4885 |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | QPCT, QPCTL, GGCT | CYP1A2 4542/4885CYP3A4 4514/4885CYP2D6 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.